KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Account Payables: 2018-2025

Historic Change in Account Payables for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $89.0 million.

  • Moderna's Change in Account Payables fell 7.29% to $89.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.0 million, marking a year-over-year increase of 2.44%. This contributed to the annual value of -$69.0 million for FY2024, which is 630.77% down from last year.
  • Per Moderna's latest filing, its Change in Account Payables stood at $89.0 million for Q3 2025, which was up 289.36% from -$47.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Change in Account Payables ranged from a high of $179.0 million in Q3 2023 and a low of -$303.0 million during Q1 2024.
  • In the last 3 years, Moderna's Change in Account Payables had a median value of $21.0 million in 2023 and averaged -$15.5 million.
  • Examining YoY changes over the last 5 years, Moderna's Change in Account Payables showed a top increase of 9,000.00% in 2021 and a maximum decrease of 1,000.00% in 2021.
  • Over the past 5 years, Moderna's Change in Account Payables (Quarterly) stood at $178.0 million in 2021, then dropped by 15.17% to $151.0 million in 2022, then slumped by 86.09% to $21.0 million in 2023, then surged by 61.90% to $34.0 million in 2024, then declined by 7.29% to $89.0 million in 2025.
  • Its last three reported values are $89.0 million in Q3 2025, -$47.0 million for Q2 2025, and -$156.0 million during Q1 2025.